Clinical Trial Update: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ramucirumab (LY3009806) in children and young adults with synovial sarcoma was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Synovial Sarcoma

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Synovial Sarcoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-09-13